EQUITY METHOD INVESTMENT	12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
EQUITY METHOD INVESTMENT	EQUITY METHOD INVESTMENT On February 21, 2022, Arteris IP (Hong Kong) Ltd. (AHK), a wholly owned subsidiary of the Company, entered into a Share Purchase and Shareholders Agreement (the SPA) with certain investors and Ningbo Transchip Information Consulting Partnership (Limited Partnership) (Management Co). The transaction closed on June 20, 2022. The Company subscribed for the registered capital of approximately $11.9 million, of which $11.6 million of the contribution was contributed in-kind by way of an interconnect solutions technology license by the Company pursuant to a five-year technology license and services agreement which can be extended automatically for another five-year term, and the remaining was paid in cash. Following the consummation of the foregoing transactions, the Company held 40.3% common stock of Transchip on a fully diluted basis. The license agreement provides Transchip the right to software licenses, services, software updates and technical support. On the closing date, the license agreement including the support and maintenance services to be provided to Transchip was valued to be $11.6 million, which was recorded as deferred income and will be recognized as other income (expense), net over a period of ten years on a straight-line basis after delivery of the license. The license was delivered to Transchip on September 2, 2022. For the year ended December 31, 2024, the Company recognized income of $1.2 million for the license agreement. The Company’s ownership interest of Transchip’s registered capital was 35.0% on a fully diluted basis as of December 31, 2024. The Company accounts for its common stock investment in Transchip as an equity method investment as it does not control but has significant influence over operating and financing policies of Transchip. Transchip is the Company’s only equity method investment. As of December 31, 2024, the carrying value of the investment in Transchip was $5.8 million. The Company’s loss from its proportionate share of its equity method investment in Transchip was $2.7 million for the year ended December 31, 2024. Management reviews its investment in Transchip for impairment if and when circumstances indicate that a decline in fair value below its carrying amount may have occurred. The Company identified certain factors which could indicate a decline in fair value of its equity method investment. After completing its impairment assessment based on the prevailing facts and circumstances, management determined that the impairment condition was not considered other than temporary. As such, no impairment charge has been recognized during the year ended December 31, 2024. Management will continue to closely monitor future events and developments that would impact its assessment and if future facts and circumstances indicate that decline in fair value of the investment is other than temporary, a significant impairment may be recorded.

On February 21, 2022, Arteris IP (Hong Kong) Ltd. (AHK), a wholly owned subsidiary of the Company, entered into a Share Purchase and Shareholders Agreement (the SPA) with certain investors and Ningbo Transchip Information Consulting Partnership (Limited Partnership) (Management Co). The transaction closed on June 20, 2022.

The Company subscribed for the registered capital of approximately $11.9 million, of which $11.6 million of the contribution was contributed in-kind by way of an interconnect solutions technology license by the Company pursuant to a five-year technology license and services agreement which can be extended automatically for another five-year term, and the remaining was paid in cash. Following the consummation of the foregoing transactions, the Company held 40.3% common stock of Transchip on a fully diluted basis.

The license agreement provides Transchip the right to software licenses, services, software updates and technical support. On the closing date, the license agreement including the support and maintenance services to be provided to Transchip was valued to be $11.6 million, which was recorded as deferred income and will be recognized as other income (expense), net over a period of ten years on a straight-line basis after delivery of the license. The license was delivered to Transchip on September 2, 2022. For the year ended December 31, 2024, the Company recognized income of $1.2 million for the license agreement.

The Company’s ownership interest of Transchip’s registered capital was 35.0% on a fully diluted basis as of December 31, 2024. The Company accounts for its common stock investment in Transchip as an equity method investment as it does not control but has significant influence over operating and financing policies of Transchip. Transchip is the Company’s only equity method investment.

As of December 31, 2024, the carrying value of the investment in Transchip was $5.8 million. The Company’s loss from its proportionate share of its equity method investment in Transchip was $2.7 million for the year ended December 31, 2024. Management reviews its investment in Transchip for impairment if and when circumstances indicate that a decline in fair value below its carrying amount may have occurred. The Company identified certain factors which could indicate a decline in fair value of its equity method investment. After completing its impairment assessment based on the prevailing facts and circumstances, management determined that the impairment condition was not considered other than temporary. As such, no impairment charge has been recognized during the year ended December 31, 2024. Management will continue to closely monitor future events and developments that would impact its assessment and if future facts and circumstances indicate that decline in fair value of the investment is other than temporary, a significant impairment may be recorded.